Depression Therapeutics Market Global Report 2026

The depression therapeutics market size has grown strongly in recent years. It will grow from $12.76 billion in 2025 to $13.51 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to growing prevalence of depressive disorders, increasing awareness of mental health conditions, expansion of psychiatric healthcare services, rising acceptance of antidepressant medications, improvements in clinical diagnosis of depression.

The depression therapeutics market size is expected to see strongly grown in the next few years. It will grow to $17.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing demand for personalized mental health treatments, expansion of innovative antidepressant drug pipelines, growing healthcare expenditure on mental health services, rising focus on early intervention and prevention programs, increasing regulatory support for novel depression therapies. Major trends in the forecast period include increasing adoption of rapid acting antidepressant therapies, growing utilization of combination treatment approaches for depression management, expansion of personalized medication selection strategies, rising focus on treatment resistant depression management, increasing development of novel antidepressant drug classes.

The increasing prevalence of depression disorders is expected to propel the growth of the depression therapeutics market going forward. Depression refers to a common mental health disorder characterized by persistent low mood, loss of interest or pleasure in activities, and a range of emotional and physical symptoms that affect daily functioning. The increasing prevalence of depression disorders is driven by rising psychosocial stress, including chronic exposure to emotional pressure from work, relationships, financial difficulties, and social expectations that overwhelm an individual's coping capacity. Depression therapeutics help manage depression by targeting underlying neurochemical imbalances and mood regulation pathways to reduce symptoms, improve emotional stability, and restore normal functioning. For instance, in May 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022-23, spending on mental health conditions and substance use disorders accounted for nearly 7% ($11.9 billion) of total expenditures across broad disease groups. More than half of this amount, 52% or $6.1 billion, was spent on public hospitals. During the same period, from January 2022 to April 2023, an estimated 26% of Australians aged 15 and over were living with a mental illness. Therefore, the increasing prevalence of depression disorders is driving the growth of the depression therapeutics market.

Key companies operating in the depression therapeutics market are focusing on developing innovative treatments, such as novel neuroactive antidepressant agents, to improve rapid symptom relief, enhance treatment response rates, and address limitations of traditional antidepressants. Novel neuroactive antidepressant agents are a new class of depression treatments that act on brain signaling systems to provide faster and more targeted relief of depressive symptoms compared to traditional antidepressants. For example, in March 2026, Shionogi and Co. Ltd., a Japan-based pharmaceutical company, launched ZURZUVAE (zuranolone) 30 mg capsules for the treatment of major depressive disorder (MDD). The therapy is designed as a neuroactive steroid that modulates GABA-A receptors, helping to restore neural balance and provide rapid reduction in depressive symptoms. It is intended as an oral short-course treatment option, offering a novel approach compared to traditional long-term antidepressant regimens, and aims to improve patient outcomes by delivering faster symptom relief and better tolerability in adults diagnosed with major depressive disorder.

In July 2025, Supernus Pharmaceuticals Inc., a US-based specialty biopharmaceutical firm, acquired Sage Therapeutics Inc. for $561 million. Through this acquisition, Supernus aims to expand its central nervous system therapeutics portfolio by strengthening its presence in depression treatment and gaining access to innovative neuropsychiatric therapies. Sage Therapeutics Inc. is a US-based biopharmaceutical company that provides depression therapeutics, specifically focusing on rapid-acting treatments for postpartum depression (PPD) and major depressive disorder (MDD).

Major companies operating in the depression therapeutics market are Johnson & Johnson; Eli Lilly and Company; Pfizer Inc.; GSK plc; H. Lundbeck A/S.

North America was the largest region in the depression therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the depression therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the depression therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The depression therapeutics market consists of sales of neurostimulation therapies, neuroactive steroid antidepressants, psychedelic-assisted therapies, and digital therapeutics and prescription mental health software platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The depression therapeutics market research report is one of a series of new reports that provides depression therapeutics market statistics, including depression therapeutics industry global market size, regional shares, competitors with a depression therapeutics market share, detailed depression therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the depression therapeutics industry. This depression therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.